# Endogenex

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/endogenex

- Industry: Medical Devices & Equipment
- Headquarters: Plymouth, US
- Website: www.endogenex.com
- Total disclosed funding: $130M
- Latest round: Series C (Mar 25, 2026)
- Investors on record: 8

## About

Based in Minnesota, US, and founded in 2017, Endogenex, Inc., previously known as DyaMX Inc., is the developer of a unique endoscopic method for the treatment of type 2 diabetes. In March 2026, Endogenex, Inc. raised USD 50 million in series C funding led by Arboretum Ventures, with participation from other unspecified investors. The round was part of a larger USD 138 million series C funding.


The company has developed a novel endoscopic procedure to help patients with type 2 diabetes regain control of their blood glucose levels. The Endogenex medical gadget is used in the technique for endoscopic duodenal mucosal regeneration (DMR).

## Funding rounds

- Series C, Mar 25, 2026, $50M — Arboretum Ventures
- Series C, Jun 13, 2024, $70M — Mayo Clinic Ventures, Hatteras Venture Partners, Longitude Capital, Sante Ventures, Orlando Health Ventures, Intuitive Ventures, Lumira Ventures
- Series A, Nov 30, 2018, $10M — Sante Ventures

## Investors

- Sante Ventures (https://capitalatlas.ai/funds/sante-ventures) — Series A, Series C
- Mayo Clinic Ventures (https://capitalatlas.ai/funds/mayo-clinic-ventures) — Series C
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series C
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series C
- Orlando Health Ventures — Series C
- Intuitive Ventures (https://capitalatlas.ai/funds/intuitive-ventures) — Series C
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series C
- Arboretum Ventures (https://capitalatlas.ai/funds/arboretum-ventures) — Series C